Clinical trials: Neuroblastoma (NB), open to volunteers
Neuroblastoma (NB), Neuroblastoma in Children
Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children
This is a Phase II clinical trial investigating the effectiveness and safety of a four-drug combination-Chidamide, Dinutuximab Beta, Irinotecan, and Temozolomide-for children with relapsed or refractory neuroblastoma.
- Trial name
- NCT07318831
- Testing
- Chidamide Combined with Dinutuximab Beta, Irinotecan, and Temozolomide
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Neuroblastoma (NB)
Safety, Tolerability, and Preliminary Efficacy of [211At]MABG in Patients With Relapsed or Refractory Neuroblastoma
Fractionated dosing of [211At]MABG Radiotherapy in Relapsed/Refractory Neuroblastoma
- Trial name
- NCT07767630
- Testing
- [211At]MABG
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Sichuan University
Neuroblastoma (NB), Ganglioneuroblastoma
Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma
Neuroblastoma (NB) is a malignant neoplasm of the sympathetic nervous system, occurring in 1 in 8,000 live births, accounting for 6-10% of all childhood malignant neoplasms and responsible for 12-15% of mortality -, making it the…
- Trial name
- NB-NK-2026 (NCT07375563)
- Testing
- Dinutuximab beta, temozolomide, irinotecan, autologous NK cell, irinotecan, temozolomide, dinutuximab beta, NK-cell product
- Where
- Russia
- Volunteers
- 5 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Neuroblastoma (NB)
Clinical Application Study of [123I]Metaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of Neuroblastoma
The goal of this prospective observational study is to evaluate the diagnostic performance of ¹²³I-MIBG SPECT/CT and SSTR PET in Chinese children with suspected or confirmed neuroblastoma (NB).
- Trial name
- MIBG & SSTR NB (NCT07064746)
- Testing
- ¹²³I-MIBG SPECT/CT, SSTR PET
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Neuroblastoma (NB), Prognosis
Risk Model for Metastasis Detection of Neuroblastoma
Neuroblastoma (NB) is the most common extracranial solid tumor in children, accounting for about 15% of tumor-related mortality.
- Conditions
- Neuroblastoma (NB), Prognosis, Bone Marrow Metastasis, Bone Metastases
- Trial name
- NB (NCT06703944)
- Testing
- risk model in diagnosis and prognosis
- Where
- 3 sites in China
- Volunteers
- 500 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Neuroblastoma, Recurrent, Refractory, Neuroblastoma (NB)
Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma
The goal of this clinical trial is to assess safety and efficacy of systemic injection of allogenic NK cells in patients with refractory/recurrent high-risk neuroblastoma.
- Conditions
- Neuroblastoma, Recurrent, Refractory, Neuroblastoma (NB), Neuroblastoma in Children
- Trial name
- NCT06674265
- Testing
- Allogenic NK cells infusion
- Where
- Iran
- Volunteers
- 10 people
- Sponsor
- Marzieh Ebrahimi
Quality of Life (QOL), Patient-Reported Outcome Measures (PROMs)
Validation of the EQ-5D-Y-3L and EQ-5D-Y-5L for Paediatric Patients in China
The goal of this observational study is to validate the EQ-5D-Y-3L and EQ-5D-Y-5L in measuring health-related quality of life (HRQoL) for paediatric patients with different health conditions in China.
- Conditions
- Quality of Life (QOL), Patient-Reported Outcome Measures (PROMs), Pneumonia Childhood, Neuroblastoma (NB)
- Trial name
- NCT06873672
- Where
- China
- Volunteers
- 360 people
- Sponsor
- RenJi Hospital
Neuroblastoma (NB), Desmoplastic Small Round Cell Tumor (DSRCT)
Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial.
Title: Safety and efficacy of CAR-T cell therapy for relapsed/refractory neuroblastoma and desmoplastic small round cell tumors: a single-arm, open-label trial.
- Trial name
- NCT06836505
- Testing
- CART therapy
- Where
- 3 sites in China
- Volunteers
- 10 people
- Sponsor
- Sun Yat-Sen University Cancer Center